Protherics plc (PTIL)

[surf1944]

Protherics PLC announces Licensing Agreement

Protherics PLC

Protherics signs ReGel(TM) licensing agreement
with Myungmoon Pharm.

London, UK; Brentwood, TN, US; 25 September 2007 - Protherics PLC ("Protherics"
or the "Company"), the international biopharmaceutical company focused on
critical care and cancer, today announces that it has signed a licensing
agreement with Myungmoon Pharm. Co. Ltd., a Korean pharmaceutical company,
granting it the rights to develop anti-inflammatory products using Protherics'
novel proprietary local, sustained release drug delivery system ReGel(TM).

Protherics will receive a small upfront payment on signing the agreement and
royalties on any net sales in the Republic of Korea. Under the agreement,
Protherics also has an option on agreed terms to the global rights outside of
the Republic of Korea to any products developed under the agreement.

Mr G.H. Lee, President of Myungmoon Pharm. Co. Ltd. commented:

"We are excited to have signed this agreement to use ReGel in the development of
locally administered, sustained release anti-inflammatory products for arthritis
and other potential indications."

Andrew Heath, Chief Executive of Protherics commented:

"Protherics' ReGel is a unique drug delivery system, gained through our
acquisition of MacroMed Inc, which has broad applicability beyond its use in
OncoGel, our proprietary formulation of paclitaxel in phase II development for
cancer. There is encouraging interest from a number of major companies to
develop products utilising ReGel for a range of indications."